Reviewing Morphic Holding Inc. (MORF)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

Morphic Holding Inc. (NASDAQ:MORF) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Morphic Holding Inc. and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both businesses.

Liquidity

The current Quick Ratio of Morphic Holding Inc. is 4.6 while its Current Ratio is 4.6. Meanwhile, Brainstorm Cell Therapeutics Inc. has a Current Ratio of 1 while its Quick Ratio is 1. Morphic Holding Inc. is better positioned to pay off its short-term and long-term debts than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

In next table is given Morphic Holding Inc. and Brainstorm Cell Therapeutics Inc.s ratings and recommendations.

The average price target of Morphic Holding Inc. is $32, with potential upside of 134.78%.

Institutional & Insider Ownership

Morphic Holding Inc. and Brainstorm Cell Therapeutics Inc. has shares held by institutional investors as follows: 49.9% and 11.4%. Insiders held roughly 26.4% of Morphic Holding Inc.s shares. Comparatively, Brainstorm Cell Therapeutics Inc. has 0.6% of its share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Morphic Holding Inc.s stock price has bigger growth than Brainstorm Cell Therapeutics Inc.

Summary

Morphic Holding Inc. beats Brainstorm Cell Therapeutics Inc. on 6 of the 8 factors.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to read the rest:
Reviewing Morphic Holding Inc. (MORF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly